{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:02Z","timestamp":1790717042317,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T00:00:00Z","timestamp":1536278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases. This exceptional response should instigate further research efforts with this protocol, which consists only of approved drugs and treatments.<\/jats:p>","DOI":"10.1177\/1534735418794867","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T02:05:38Z","timestamp":1536372338000},"page":"1297-1303","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2"],"prefix":"10.1177","volume":"17","author":[{"given":"Ralf","family":"Kleef","sequence":"first","affiliation":[{"name":"Immunology & Integrative Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Moss","sequence":"additional","affiliation":[{"name":"Cancer Decisions, Lemont, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marcell","family":"Szasz","sequence":"additional","affiliation":[{"name":"Semmelweis University, Budapest, Hungary"},{"name":"Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bohdjalian","sequence":"additional","affiliation":[{"name":"Rudolfinerhaus Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Bojar","sequence":"additional","affiliation":[{"name":"NextGen Oncology Group, Dusseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Bakacs","sequence":"additional","affiliation":[{"name":"PRET Therapeutics Ltd, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"bibr1-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"bibr2-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.11.019"},{"key":"bibr3-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"bibr4-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0247"},{"key":"bibr5-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1007\/BF03168992"},{"key":"bibr6-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1159\/000049008"},{"key":"bibr7-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2013.10.004"},{"key":"bibr8-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4315-0"},{"key":"bibr9-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1007\/s13244-015-0447-4"},{"key":"bibr10-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0197"},{"key":"bibr11-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1031"},{"key":"bibr12-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0134"},{"key":"bibr13-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"bibr14-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"bibr15-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35"},{"key":"bibr16-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806075105"},{"key":"bibr17-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813175106"},{"key":"bibr18-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0569"},{"key":"bibr19-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1138"},{"key":"bibr20-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01753.x"},{"key":"bibr21-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1026507"},{"key":"bibr22-1534735418794867","first-page":"550","volume":"10","author":"Skitzki JJ","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"bibr23-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0118"},{"key":"bibr24-1534735418794867","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2012.677933"},{"key":"bibr25-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"bibr26-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-013-2922-9"},{"key":"bibr27-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"key":"bibr28-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2005.02.001"},{"key":"bibr29-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1007\/BF03168959"},{"key":"bibr30-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1126\/science.340.6130.263"},{"key":"bibr31-1534735418794867","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980707"},{"key":"bibr32-1534735418794867","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321"}],"updated-by":[{"DOI":"10.1177\/1534735419854816","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000}}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735418794867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1534735418794867","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735418794867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:19:01Z","timestamp":1777454341000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1534735418794867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1177\/1534735418794867"],"URL":"https:\/\/doi.org\/10.1177\/1534735418794867","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]}}}